Lonza has announced that it will invest CHf 85 million (~$94 million) at 8 of its Capsugel manufacturing sites around the world to expand its capsule manufacturing capacity by 15%, or 30 billion capsules per year. The expansion will involve multiple lines of capsules, including the Zephyr range and other DPI capsules.
Lonza acquired Capsugel in 2017, and the company launched the Zephyr line of DPI capsules in 2019. The sites that will be expanded are located in Belgium, France, the US, India, Indonesia, Mexico, Japan, and China.
Lonza Capsules & Health Ingredients President Claude Dartiguelongue said, “We continue to see strong demand for our products across all markets, as consumers and patients alike take a more active interest in their health. Therefore, we felt it is critical that we make this commitment to expand the manufacturing capacity of our network, not only addressing supply needs in the near term but also supply availability over the long term.”
Read the Lonza press release.
